AMENDED AND RESTATED WORLDWIDE AGREEMENTWorldwide Agreement • November 12th, 2003 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances) • California
Contract Type FiledNovember 12th, 2003 Company Industry JurisdictionThis Amended and Restated Worldwide Agreement is entered into as of October 1, 2003 (the “Effective Date”), by and among, on the one hand, HOFFMANN-LA ROCHE INC., a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche-Nutley”) and F. HOFFMANN-LA ROCHE LTD of Basel, Switzerland (“F. Roche”) (Roche-Nutley and F. Roche are hereinafter individually and collectively referred to as “Roche”) and, on the other hand, PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”).
SUBLEASESublease • November 12th, 2003 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
Contract Type FiledNovember 12th, 2003 Company IndustryTHIS SUBLEASE (“Sublease”) is made as of July 31, 2003 by and between PROTEIN DESIGN LABS, INC., a Delaware corporation (“Subtenant”), and ABGENIX, INC., a Delaware corporation (“Sublandlord”).
ICOS CORPORATION MANUFACTURING AGREEMENTManufacturing Agreement • November 12th, 2003 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
Contract Type FiledNovember 12th, 2003 Company IndustryTHIS MANUFACTURING AGREEMENT (this “Agreement”) between ICOS Corporation, a Washington corporation, having its principal offices at 22021 20th Avenue, Bothell, WA 98021 (“ICOS”), and Protein Design Labs, Inc., a Delaware corporation, having its principal offices at34801 Campus Drive, Fremont, CA 94555 (“PDL”), is effective as of August 29, 2003.
SECOND AMENDMENT TO SUBLEASE Early Termination of the Entire PremisesSublease • November 12th, 2003 • Protein Design Labs Inc/De • Biological products, (no disgnostic substances)
Contract Type FiledNovember 12th, 2003 Company IndustryThis Second Amendment effective October 1, 2003, (the “Second Amendment”) is to the Sublease effective March 7, 2000, as amended September 3, 2002, (the “Sublease”) by and between FibroGen, Inc. (“Sublessor”) and EOS Biotechnology, Inc. (the “Sublessee”) (collectively, the “Parties”). Unless otherwise defined herein, any capitalized terms shall have the meaning ascribed to them in the Sublease.